Related Experiment Video
Updated: Mar 25, 2026
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Cardiac monitoring of high-dose verapamil in cluster headache: An international Delphi study
H Koppen1, J Stolwijk2, E B Wilms3
1Department of Neurology, Haga Hospital, The Netherlands h.koppen@hagaziekenhuis.nl.
Insights
High-dose verapamil (HDV) effectively treats cluster headaches, but cardiac risks necessitate guidelines. Experts recommend pretreatment EKGs for screening, though monitoring during HDV treatment remains debated.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- High-dose verapamil (HDV) is a crucial prophylactic treatment for cluster headaches.
- Cardiac adverse events and EKG abnormalities are common in patients on HDV.
- Evidence-based guidelines for screening and monitoring HDV use are lacking.
Purpose of the Study:
- To formulate EKG guidelines for cluster headache patients using HDV.
- To establish pretreatment screening and monitoring protocols.
- To address the lack of evidence-based recommendations.
Main Methods:
- Delphi approach utilized.
- 22 international clinical experts in cardiac rhythm disorders were interviewed.
- Guidelines for EKG screening and monitoring were developed.
Main Results:
- Unanimous agreement on pretreatment EKG for arrhythmia screening.
- Most experts found pretreatment EKG unnecessary for patients without prior cardiac events on HDV.
- Half the panel recommended Holter EKG for patients on verapamil ≥ 480 mg/day.
- Recommended maximum daily doses varied (240–960 mg).
- Contraindications largely aligned with FDA guidelines.
Conclusions:
- Consensus reached on pretreatment EKG monitoring.
- No consensus achieved on EKG monitoring during HDV treatment or dose adjustments.
Background:
In many patients, high-dose verapamil (HDV) is the only effective prophylactic treatment for cluster headache. Although cardiac adverse events and EKG abnormalities are relatively common, evidence-based guidelines for screening and monitoring patients on HDV are lacking.
Goal And Methods:
Using the Delphi approach, we interviewed 22 international clinical experts in cardiac rhythm disorders to formulate EKG guidelines for the pretreatment screening and monitoring of cluster headache patients using HDV.
Results:
The panel agreed only on performing pretreatment EKG to screen for pre-existing cardiac arrhythmia. Pretreatment EKG was deemed not necessary by most panel members for patients who did not have cardiac adverse events during a previous period of cluster headache attacks treated with HDV. Half the panel advised Holter EKG for patients on verapamil ≥ 480 mg/day. The highest recommended daily doses varied between 240 and 960 mg. Contraindications for use of verapamil largely followed FDA guidelines.
Discussion:
Experts in cardiac rhythm disorders agreed on pretreatment EKG monitoring, but no consensus was reached on EKG monitoring during HDV treatment and around dose adjustments.
Related Concept Videos
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:30Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:23Holter Monitor: 24-Hour Monitoring
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy